[go: up one dir, main page]

FR2969611B1 - Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) - Google Patents

Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Info

Publication number
FR2969611B1
FR2969611B1 FR1061304A FR1061304A FR2969611B1 FR 2969611 B1 FR2969611 B1 FR 2969611B1 FR 1061304 A FR1061304 A FR 1061304A FR 1061304 A FR1061304 A FR 1061304A FR 2969611 B1 FR2969611 B1 FR 2969611B1
Authority
FR
France
Prior art keywords
pkb
preparation
pharmaceutical use
akt phosphorylation
thiazole derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1061304A
Other languages
English (en)
Other versions
FR2969611A1 (fr
Inventor
Jean Christophe Carry
Victor Certal
Frank Halley
Karl Andreas Karlsson
Laurent Schio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR1061304A priority Critical patent/FR2969611B1/fr
Publication of FR2969611A1 publication Critical patent/FR2969611A1/fr
Application granted granted Critical
Publication of FR2969611B1 publication Critical patent/FR2969611B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR1061304A 2010-12-28 2010-12-28 Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) Expired - Fee Related FR2969611B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1061304A FR2969611B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1061304A FR2969611B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Publications (2)

Publication Number Publication Date
FR2969611A1 FR2969611A1 (fr) 2012-06-29
FR2969611B1 true FR2969611B1 (fr) 2013-02-08

Family

ID=44064716

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1061304A Expired - Fee Related FR2969611B1 (fr) 2010-12-28 2010-12-28 Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Country Status (1)

Country Link
FR (1) FR2969611B1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268345A1 (en) 2020-05-05 2022-11-10 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2021226208A2 (fr) 2020-05-05 2021-11-11 Nuvalent, Inc. Agents chimiothérapeutiques à base d'éthers macrocycliques hétéroaromatiques
KR20240087788A (ko) 2021-10-01 2024-06-19 뉴베일런트, 아이엔씨. 헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101405278A (zh) * 2006-03-15 2009-04-08 4Sc股份公司 新颖的杂环NF-κB抑制剂
GB0620818D0 (en) * 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
GB0723747D0 (en) * 2007-12-04 2008-12-31 Ucb Pharma Sa Therapeutic agents
GB0805818D0 (en) * 2008-03-31 2008-04-30 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
FR2969611A1 (fr) 2012-06-29

Similar Documents

Publication Publication Date Title
FR2954317B1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
HUS1900012I1 (hu) Vegyületek és készítmények protein-kináz inhibitorokként
FR2954315B1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
BR112013023174A2 (pt) "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos"
BR112013011949A2 (pt) "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis"
HUE041909T2 (hu) Eljárás DOPO-származék vegyületek elõállítására és azok készítményei
BR112013015010A2 (pt) produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
PT2658844T (pt) Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb)
MA28941B1 (fr) Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP2580206A4 (fr) Composition pharmaceutique comprenant un dérivé d'amide ou son sel pharmaceutiquement acceptable
EP2190445A4 (fr) Pousses de grenade, préparations issues de celles-ci et compositions les comprenant
EP2637655A4 (fr) Composition pharmaceutique de taxoïdes
EP2633862A4 (fr) Compositions à base de nanocapsules de propolis utilisables comme supports de substances d'intérêt, procédé d'obtention et utilisation
FR2896504B1 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2011123524A3 (fr) Macrolides inhibiteurs de mtor
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
EP2758384A4 (fr) Dérivé de benzothiazole contenant phénylimide ou son sel et composition pharmaceutique le comprenant
EA201400444A1 (ru) Производные 2-оксопиперидинила
FR2969611B1 (fr) Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2940086B1 (fr) Formulation pharmaceutique de fenofibrate nanonise
FR2968309B1 (fr) Nouveaux epaississants cationiques, utilisables sur une large gamme de ph procede pour leur preparation et composition en contenant.
FR2951169B1 (fr) Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947547B1 (fr) Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
FR2969609B1 (fr) Nouveaux derives de 6-oxo-dihydro-pyrimidine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160831